Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization
- Department of Microbiology and Immunology, Weill Cornell Medicine, United States
Tables
Table 1
Passive immunization with convalescent plasma (CP) during SARS-CoV-1 and SARS-CoV-2 infection.
| Reference | Virus | Antibody source | Number of patients | Efficacy | Safety |
|---|---|---|---|---|---|
Cheng et al., 2005 | SARS-CoV-1 | CP 160–640 ml Seropositive titer range: 160–2,560 | 80 patients with SARS | Better outcome with plasma before than after day 14 | No immediate adverse effects |
Yeh et al., 2005 | SARS-CoV-1 | CP 500 ml IF IgG titer >640 | 3 hospital workers with SARS | Drop within 24 hr in viral load from ~ 105 to < 1 RNA copies/ml | No significant side effects |
Soo et al., 2004 | SARS-CoV-1 | CP Ab titers not measured | 19 (plasma) vs. 21 (methylprednisolone) SARS patients | Faster release, lower mortality with plasma than comparator | No immediate adverse effects |
Shen et al., 2020 | SARS-CoV-2 | CP 400 ml Ab binding >1000 NAb > 40 | 5 COVID-19 patients | Reduced viral load, clinical improvement Release of 3/5 | None reported |
Duan et al., 2020 | SARS-CoV-2 | CP 200 ml NAb > 640 | 10 COVID-19 patients | Virus undetectable in 7/10 Varying clinical, laboratory, radiological improvements | No adverse effects observed |
Zhang et al., 2020 | SARS-CoV-2 | CP 200–2,400 ml Ab not measured | 4 COVID-19 patients | Negative PCR Pulmonological improvements Discharge of 3/4 | No adverse effects observed |
Ahn et al., 2020 | SARS-CoV-2 | CP 2 × 250 ml Binding IgG detected by ELISA | 2 COVID-19 patients | Reduced sputum viral load Radiological and clinical improvements | No adverse effects observed |
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization
eLife 9:e57877.
https://doi.org/10.7554/eLife.57877
